Prior trials failed due to poor trial design and decisions made by management during the trails as confirmed by FDA.
That we continue to get promising anecdotal information when LL is administered by third party medical teams and fails in Nader’s hands raises the question of … WHY???
Why does LL fail when NP conducts a submission or trial?? Why?
Market Data 
Markets 
AI
